We’ve seen a radical evolution in the types of medication and available diagnostics for treating different diseases.
This really came to a head back in 2020, when the race to find a cure for COVID-19 triggered a tidal wave of new interest in biotech stocks. New investment flooded in, and the industry grew by $284 billion.
Prices quickly got ahead of themselves, and these new investors didn’t stick around for long. As post-Covid “reopening” trades came to dominate, biotech and genomics stocks got left behind.
But despite the sector’s post-COVID setbacks, we know the 2020s will be the decade where market-leading stocks come from biotech and DNA technology…
This post appeared first on Money & Markets, LLC.